Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40

Autor/inn/en	Boone, Margaret; Brown, Nancy J.; Moon, Mary A.; Schuman, Deborah J.; Thomas, Josephine; Wright, Denise L.
Institution	American Institutes for Research, Washington, DC.
Titel	Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40
Quelle	(2004), (198 Seiten) PDF als Volltext (1); PDF als Volltext kostenfreie Datei (2) Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Monographie
Schlagwörter	Leitfaden; Pharmacology; Physicians; Guidelines; Physiology; Drug Addiction; Substance Abuse; Psychiatry; Patients; Population Groups; Legal Problems; Intervention; Drug Therapy; Drug Use; Outcomes of Treatment; Drug Rehabilitation; United States + Suchen Sie Ihr Suchwort? Arzneikunde; Physician; Doctor; Arzt; Richtlinien; Physiologie; Drug dependence; Drug consomption; Drogenabhängigkeit; Drug use; Drogenkonsum; Psychiatrie; Patient; Drug consumption; Substance abuse; Drogentherapie; USA
Abstract	This Treatment Improvement Protocol (TIP) addresses the clinical use of buprenorphine in the treatment of opioid addiction. TIPs are best-practice guidelines for the treatment of substance use disorders that make the latest research in substance abuse treatment available to counselors and educators. The content was generated by a panel of experts in the fields of addiction psychiatry, medical detoxification, and substance abuse treatment, and reviewed by independent experts. The first chapter introduces the current state of opioid addiction treatment, gives practical guidelines for physicians, and explains the new treatment option of buprenorphine for opioid addiction. Chapter two explores the pharmacology and effectiveness of buprenorphine, alone and in combination with naloxone, as well as the issues of adverse reactions and interactions with other drugs. Chapter three focuses on the patient: determining the presence and nature of the patient's opioid use disorder, and his or her suitability for buprenorphine treatment. The fourth chapter contains treatment protocols for patient opioid detoxification, maintenance and management with buprenorphine. Chapter five discusses special populations of people with opioid use disorder, including pregnant women, adolescents, patients with pain and/or co-morbid conditions, and healthcare professionals who are addicted to opioids. Regulations, policies, procedures, and legal issues are covered in chapter six. Appended are: (1) Bibliography; (2)Assessment and Screening Instruments; (3) DSM-IV-TR Material; (4) Consent to Release of Information Under Title 42, Part 2, Code of Federal Regulations; (5) Clinical Toolbox: Chapter 3 Supplemental Information; (6) Federation of State Medical Boards--Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office; (7) Stages of Change; (8) Sample Treatment Agreement/Contract; (9) Glossary; and (10) Field Reviewers. (Contains 6 figures.) (ERIC).
Anmerkungen	SAMHSA's National Clearinghouse for Alcohol and Drug Information (NCADI), P.O. Box 2345, Rockville, MD 20847-2345. Tel: 800-729-6686 (Toll Free); Tel: 301-468-2600; TDD: 800-487-4889 (Toll Free).
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10